文献速递膀胱癌与上尿路尿路上皮癌

高危上尿路尿路上皮癌新辅助化疗后行根治性手术的II期试验

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
PubMed 文献 · J Urol · 2019-11-08

这项多机构前瞻性II期试验评估高危上尿路尿路上皮癌患者接受新辅助化疗后的病理完全缓解率。加速MVAC组29例可评估患者中3例(10.3%)达到ypT0N0,病理完全缓解率13.8%(90%CI 4.9-28.8),3-4级毒性发生率23%,无5级事件。吉西他滨+卡铂组因入组不佳关闭。

要点

  • 加速MVAC新辅助化疗在高危UTUC中安全,病理完全缓解率13.8%。
  • 超过60%患者最终病理分期≤ypT1,结果令人鼓舞。
  • 吉西他滨+卡铂组因入组不佳提前关闭,数据有限。

核心结论

  • 在高危上尿路尿路上皮癌且肌酐清除率大于50 ml/min的患者中,加速MVAC新辅助化疗安全并达到预设活性,病理完全缓解率约14%。
  • 超过60%患者最终病理分期为ypT1或更低,支持在合适患者中使用新辅助化疗。

研究设计与样本

  • 多机构、前瞻性、II期试验,计划每臂入组30例。
  • 高危上尿路尿路上皮癌计划行肾输尿管切除术患者,肌酐清除率大于50 ml/min者接受4周期加速MVAC,30-50 ml/min者接受吉西他滨+卡铂。
  • 主要终点为病理完全缓解(ypT0N0),预设18%值得进一步研究而4%不足以支持继续。

主要发现

  • 加速MVAC组2015-2017年入组30例,29例可评估(23男6女,中位年龄65岁,范围40-84),80%完成全部计划治疗。
  • 3例(10.3%)达到ypT0N0,另1例达到ypT0Nx,病理完全缓解率13.8%(90%CI 4.9-28.8)。
  • 1例因4级脓毒症推迟肾输尿管切除术;加速MVAC组3-4级毒性发生率23%,无5级事件。
  • 吉西他滨+卡铂组仅入组6例,因入组不佳关闭。

关键数值与推荐

  • 加速MVAC组29例可评估患者中3例(10.3%)达到ypT0N0,病理完全缓解率13.8%(90%CI 4.9-28.8)。
  • 加速MVAC组3-4级毒性发生率23%,无5级事件。
  • 超过60%患者最终病理分期为ypT1或更低。

临床怎么用

  • 对肌酐清除率大于50 ml/min的高危上尿路尿路上皮癌患者,可考虑加速MVAC新辅助化疗后行根治性手术。
  • 治疗期间需监测3-4级毒性(本组发生率23%)及感染事件。

局限性

  • 吉西他滨+卡铂组因入组不佳关闭,该人群数据有限。
  • 单臂设计、样本量小,病理完全缓解率置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated pathological complete responses after neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma. MATERIALS AND METHODS: Patients with high grade upper tract urothelial carcinoma in whom nephroureterectomy was planned were assigned to 4 neoadjuvant chemotherapy cycles of accelerated methotrexate, vinblastine, doxorubicin and cisplatin in those with baseline creatinine clearance greater than 50 ml per minute or gemcitabine and carboplatin in those with creatinine clearance 30 to 50 ml per minute or less. The study primary end point was a pathological complete response (ypT0N0). The accrual goal was 30 patients per arm. An 18% pathological complete response was considered worth further study while a 4% pathological complete response would not have justified pursuing this regimen. With 28 eligible patients per arm success was defined as 3 or more pathological complete responses (10.7%) in a given arm. Secondary end points included safety, renal function and oncologic outcomes. RESULTS: A total of 30 patients enrolled in the accelerated methotrexate, vinblastine, doxorubicin and cisplatin arm from 2015 to 2017. Six patients enrolled in the gemcitabine and carboplatin arm, which closed due to poor accrual. Of the 29 patients eligible for accelerated methotrexate, vinblastine, doxorubicin and cisplatin, including 23 men and 6 women with a median age of 65 years (range 40 to 84), 80% completed all planned treatments, 3 (10.3%) achieved ypT0N0 and 1 achieved ypT0Nx for a pathological complete response in 13.8% (90% CI 4.9-28.8). In 1 patient receiving accelerated methotrexate, vinblastine, doxorubicin and cisplatin nephroureterectomy was deferred due to grade 4 sepsis. The grade 3-4 toxicity rate was 23% in the accelerated methotrexate, vinblastine, doxorubicin and cisplatin arm with no grade 5 event. CONCLUSIONS: Accelerated methotrexate, vinblastine, doxorubicin and cisplatin neoadjuvant chemotherapy in patients with high grade upper tract urothelial carcinoma and creatinine clearance greater than 50 ml per minute was safe and demonstrated predefined activity with a 14% pathological complete response rate. Final pathological stage ypT1 or less in more than 60% of patients is encouraging. Together the results of this prospective trial support the use of neoadjuvant chemotherapy in eligible patients with high grade upper tract urothelial carcinoma.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Margulis V, Puligandla M, Trabulsi EJ, et al. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2019. PMID: 31702432. doi:10.1097/JU.0000000000000644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。